JP2014526541A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014526541A5 JP2014526541A5 JP2014531244A JP2014531244A JP2014526541A5 JP 2014526541 A5 JP2014526541 A5 JP 2014526541A5 JP 2014531244 A JP2014531244 A JP 2014531244A JP 2014531244 A JP2014531244 A JP 2014531244A JP 2014526541 A5 JP2014526541 A5 JP 2014526541A5
- Authority
- JP
- Japan
- Prior art keywords
- inh
- immunoglobulin
- combination
- administered
- ivig
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000055157 Complement C1 Inhibitor Human genes 0.000 claims 24
- 108700040183 Complement C1 Inhibitor Proteins 0.000 claims 24
- 229940009550 c1 esterase inhibitor Drugs 0.000 claims 24
- 108060003951 Immunoglobulin Proteins 0.000 claims 23
- 102000018358 immunoglobulin Human genes 0.000 claims 23
- 229940123965 Immunoglobulin inhibitor Drugs 0.000 claims 12
- 201000006474 Brain Ischemia Diseases 0.000 claims 6
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 6
- 206010008118 cerebral infarction Diseases 0.000 claims 6
- 206010061216 Infarction Diseases 0.000 claims 5
- 230000007574 infarction Effects 0.000 claims 5
- 230000037396 body weight Effects 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 230000035602 clotting Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000008227 sterile water for injection Substances 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 1
- -1 antibiotic Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 claims 1
- 229960003009 clopidogrel Drugs 0.000 claims 1
- 230000008021 deposition Effects 0.000 claims 1
- 229960002768 dipyridamole Drugs 0.000 claims 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229940027941 immunoglobulin g Drugs 0.000 claims 1
- 230000006749 inflammatory damage Effects 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 150000003722 vitamin derivatives Chemical class 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161538832P | 2011-09-24 | 2011-09-24 | |
| US61/538,832 | 2011-09-24 | ||
| PCT/EP2012/068643 WO2013041677A1 (en) | 2011-09-24 | 2012-09-21 | Combination therapy using immunoglobulin and c1-inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014526541A JP2014526541A (ja) | 2014-10-06 |
| JP2014526541A5 true JP2014526541A5 (enExample) | 2015-11-05 |
| JP6190368B2 JP6190368B2 (ja) | 2017-08-30 |
Family
ID=46881067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014531244A Active JP6190368B2 (ja) | 2011-09-24 | 2012-09-21 | 免疫グロブリンおよびｃ１−阻害剤を用いる組合せ療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10471142B2 (enExample) |
| EP (1) | EP2758076B1 (enExample) |
| JP (1) | JP6190368B2 (enExample) |
| KR (1) | KR101956585B1 (enExample) |
| CN (1) | CN104010656B (enExample) |
| AU (1) | AU2012311483B2 (enExample) |
| CA (1) | CA2848510A1 (enExample) |
| DK (1) | DK2758076T3 (enExample) |
| ES (1) | ES2714999T3 (enExample) |
| WO (1) | WO2013041677A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6109081B2 (ja) | 2011-03-09 | 2017-04-05 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 人工表面との接触を含む医学的手技に伴う投与のためのｆｘｉｉ阻害剤 |
| WO2014131865A1 (en) * | 2013-02-28 | 2014-09-04 | Csl Behring Gmbh | Therapeutic agent for amniotic fluid embolism |
| US10286047B2 (en) | 2013-03-08 | 2019-05-14 | Csl Behring Gmbh | Treatment and prevention of remote ischemia-reperfusion injury |
| SI2968434T1 (sl) | 2013-03-15 | 2017-11-30 | Shire Viropharma Incorporated, | C1-INH sestavki za uporabo pri preprečevanju in zdravljenju hereditarnega angioedema (HAE) |
| AU2014262890B2 (en) * | 2013-05-06 | 2019-01-31 | Takeda Pharmaceutical Company Limited | Treatment of Alzheimer's disease subpopulations with pooled immunoglobulin G |
| HUE041809T2 (hu) * | 2013-11-22 | 2019-05-28 | Shire Viropharma Inc | Eljárások antitest által közvetített kilökõdés kezelésére szervbeültetéses páciensekben C1-észteráz inhibitorral |
| DK3157548T3 (da) | 2014-06-18 | 2021-09-06 | Csl Behring Gmbh | Terapi anvendelse af en faktor xii-inhibitor i en neurotraumatisk sygdom |
| MX2017010323A (es) * | 2015-02-20 | 2017-12-07 | Csl Behring Gmbh | Formulaciones farmaceuticas de inhibidor de esterasa c1. |
| CA2986957A1 (en) | 2015-06-03 | 2016-12-08 | Children's Hospital Medical Center | Compositions and methods for treating neonatal biliary atresia |
| EP3493832A1 (en) | 2016-08-05 | 2019-06-12 | CSL Behring GmbH | Pharmaceutical formulations of c1 esterase inhibitor |
| WO2022251654A1 (en) * | 2021-05-28 | 2022-12-01 | West Virginia University Board of Governors on behalf of West Virginia University | Mitoneet ligands for use in protection from tissue ischemic reperfusion injury |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2009158A (en) * | 1934-08-01 | 1935-07-23 | Ophthalmological Foundation In | Ophthalmic ergograph |
| DE3228502A1 (de) | 1982-07-30 | 1984-02-02 | Behringwerke Ag, 3550 Marburg | Verfahren zur herstellung des c1-inaktivators und seine verwendung |
| DE4222534A1 (de) | 1992-07-09 | 1994-01-13 | Behringwerke Ag | Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura |
| DE4227762A1 (de) | 1992-08-24 | 1994-03-03 | Behringwerke Ag | Verwendung eines Kallikrein-Inhibitors zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie bestimmter Krankheiten |
| US5827832A (en) | 1995-03-06 | 1998-10-27 | Interneuron Pharmaceuticals, Inc. | Method of protecting brain tissue from cerebral infarction subsequent to ischemia |
| EP1216052A1 (en) | 1999-09-16 | 2002-06-26 | Byk Gulden Lomberg Chemische Fabrik GmbH | Combination of c1-inh and lung surfactant for the treatment of respiratory disorders |
| WO2004075837A2 (en) * | 2003-02-21 | 2004-09-10 | Tanox, Inc. | Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury |
| US8142781B2 (en) * | 2005-10-07 | 2012-03-27 | Armagen Technologies, Inc. | Fusion proteins for blood-brain barrier delivery |
| HRP20110622T1 (hr) | 2005-12-21 | 2011-09-30 | Pharming Intellectual Property B.V. | Upotreba inhibitora c1 u sprječavanju ishemijsko-reperfuzijske ozljede |
| US20100143325A1 (en) * | 2008-12-09 | 2010-06-10 | Vascular Laboratory, Inc. | Composition And Methods Involving Thrombolytic Agents |
| EP2233499A1 (en) * | 2009-03-26 | 2010-09-29 | CSL Behring AG | Antibody composition with altered Fab sialylation |
| BRPI1012082B1 (pt) | 2009-05-27 | 2022-08-16 | Takeda Pharmaceutical Company Limited | Método para preparar uma composição de igg concentrada a partir de plasma |
-
2012
- 2012-09-21 ES ES12761739T patent/ES2714999T3/es active Active
- 2012-09-21 WO PCT/EP2012/068643 patent/WO2013041677A1/en not_active Ceased
- 2012-09-21 CN CN201280046349.8A patent/CN104010656B/zh active Active
- 2012-09-21 EP EP12761739.7A patent/EP2758076B1/en active Active
- 2012-09-21 CA CA2848510A patent/CA2848510A1/en active Pending
- 2012-09-21 JP JP2014531244A patent/JP6190368B2/ja active Active
- 2012-09-21 AU AU2012311483A patent/AU2012311483B2/en active Active
- 2012-09-21 DK DK12761739.7T patent/DK2758076T3/en active
- 2012-09-21 KR KR1020147010605A patent/KR101956585B1/ko active Active
- 2012-09-21 US US14/346,478 patent/US10471142B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014526541A5 (enExample) | ||
| HK1198869A1 (en) | Combination treatments for hepatitis c | |
| WO2009043464A3 (en) | Astressin and beta- endorphin for use as therapeutic agents | |
| IL314873A (en) | Compositions and methods for treating disorders ameliorated by muscarnic receptor activation | |
| JP2013522229A5 (enExample) | ||
| WO2009043465A3 (en) | Use of beta-endorphin as a therapeutic agent | |
| WO2009043504A3 (en) | Use of apelin-36 and optionally beta-melanotropin as therapeutic agents, eg for treating aids or alzheimer | |
| HK1203514A1 (en) | D-amino acid compounds for liver disease | |
| JP2011509252A5 (enExample) | ||
| WO2013022846A3 (en) | Flavonoid compounds | |
| WO2009043437A3 (en) | Use of t140 and optionally retrocyclin-1 as therapeutic agents for the treatment of m. tuberculosis infections | |
| WO2009039982A3 (en) | Use of gip alone or in combination with dynorphin b as a therapeutic agent | |
| HK1215934A1 (zh) | 肽治疗剂及其使用方法 | |
| JP2016517421A5 (enExample) | ||
| KR20190015361A (ko) | 호중구감소증을 줄이는 조성물 및 방법 | |
| WO2009033775A3 (en) | Peptide alpmhir alone or in combination with peptide yvpfppf as therapeutic agent | |
| WO2009033657A3 (en) | Use of trp6-triptorelin and d-leu6-leuprolide as therapeutic agents | |
| JP2013532729A5 (enExample) | ||
| WO2009039986A3 (en) | Use of the peptide asn-asp-asp-cys-glu- leu-cys-val-asn-val-ala-cys-thr-gly-cys-leu alone or in combination with the peptide thr-thr-ser-gln-val- arg-pro-αrg as a therapeutic agent | |
| JP2019501881A5 (enExample) | ||
| JP2014513065A5 (enExample) | ||
| JP2015528501A5 (enExample) | ||
| WO2017182873A3 (en) | Peptide-oligourea foldamer compounds and methods of their use | |
| JP2014504636A5 (enExample) | ||
| JP2018521086A5 (enExample) |